Results 11 to 20 of about 1,763 (188)

Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC: A Case Report [PDF]

open access: yesRespirology Case Reports
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain.
Takayuki Niitsu   +10 more
doaj   +4 more sources

Association of salvage radiotherapy with survival outcomes in extracranial oligoprogression after first-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective cohort study [PDF]

open access: yesTherapeutic Advances in Medical Oncology
Background: While first-line systemic therapy is the standard of care for extensive-stage small-cell lung cancer (ES-SCLC), therapeutic failure remains nearly universal, with survival heavily dictated by progression patterns.
Jiatong Li   +8 more
doaj   +3 more sources

Acquired resistance to first-line immune checkpoint inhibitors in esophageal squamous cell carcinoma: progression patterns and prognostic implications [PDF]

open access: yesFrontiers in Immunology
BackgroundDespite the survival benefit of first-line immune checkpoint inhibitor (ICI)-based therapy in advanced esophageal squamous cell carcinoma (ESCC), acquired resistance (AR) remains a major clinical challenge, and its progression patterns and ...
Rui-Ying Zhang   +9 more
doaj   +3 more sources

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma? [PDF]

open access: yesExploration of Targeted Anti-tumor Therapy, 2023
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival.
Sviatoslav Chekhun   +11 more
doaj   +2 more sources

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study

open access: yesCancer Medicine, 2023
Background Epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) develops resistance to tyrosine kinase inhibitors (TKIs).
Chunhong Hu   +6 more
doaj   +2 more sources

Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report. [PDF]

open access: yesIJU Case Rep
ABSTRACT Introduction The role of metastasis‐directed therapy in urothelial carcinoma remains uncertain, particularly in the immune checkpoint inhibitor era. We report a case of solitary pulmonary metastasis that developed after a favorable response to pembrolizumab and was managed with metastasectomy.
Takemura K   +8 more
europepmc   +2 more sources

Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression [PDF]

open access: yesLiver Cancer
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized.
Tsung-Hao Liu   +18 more
doaj   +2 more sources

Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression [PDF]

open access: yesFrontiers in Oncology
Tyrosine kinase inhibitors (TKIs) demonstrate clear therapeutic effects in patients with HER2−positive breast cancer complicated by brain metastases.
Shen Dongxing   +4 more
doaj   +2 more sources

Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial [PDF]

open access: yesBMJ Open
Introduction Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second ...
Lei Xu   +7 more
doaj   +2 more sources

Oligoprogressive renal cell carcinoma: What is the role of surgery? [PDF]

open access: yesBJU Int
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Re C   +9 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy